<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143585</url>
  </required_header>
  <id_info>
    <org_study_id>02-065</org_study_id>
    <nct_id>NCT00143585</nct_id>
  </id_info>
  <brief_title>NOGA Angiogenesis Revascularization Therapy: Evaluation by RadioNuclide Imaging - The Northern Trial</brief_title>
  <official_title>Multicentre, Randomized,Double Blind,Placebo Controlled Trial of Myocardial Angiogenesis Using VEGF165, Intramyocardial Gene Delivery in Patients With Severe Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <brief_summary>
    <textblock>
      To demonstrate the clinical efficacy and safety of vascular endothelial growth
      factor(VEGF165)when delivered by direct myocardial injection through the NOGA navigational
      catheter to improve myocardial perfusion in patients with severe angina pectoris for whom
      conventional PCI or CABG are either not possible or not ideal.Secondary objective will be to
      determine the effects of VEGF gene therapy on angina symptoms, patient perceived quality of
      life and exercise capacity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, double blind, placebo controlled trial to assess efficacy of VEGF and promote
      myocardial angiogenesis in patients with CCS III-IV angina symptoms,treated with maximal anti
      anginal medications who are not amenable to or not ideal candidates for conventional
      revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <completion_date type="Anticipated">June 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial perfusion-stress/ rest scores(SRS),changes in summed stress scores(SSS)from baseline to 12 weeks follow up between placebo and VEGF treated groups. This analysis will be repeated at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptom evaluation (CCS class, Seattle Angina Questionnaire; patient perceived Quality of Life( SF 36 questionnaire); exercise performance; major adverse cardiac events</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Myocardial Ischemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intramyocardial delivery of either VEGF165 or placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Canadian Cardiovascular Class III-IV angina despite treatment with maximal medical
             therapy

          -  LVEF&gt;20%

          -  Ischemic defects on myocardial stress SPECT imaging

        Exclusion Criteria:

          -  NYHA&gt;2

          -  History of or diagnosis of age related macular degeneration, retinopathy

          -  Atrial fibrillation

          -  Primary valvular heart disease

          -  Evidence of or known history of cancer with in past 10 yea

          -  Uncontrolled hypertension

          -  Liability to receive dipyridamole

          -  History or diagnosis of rheumatoid arthritis

          -  Recent MI(within 4 weeks)

          -  Important ilio-femoral peripheral vascular disease, limiting catheter access

          -  History of unexplained gastrointestinal hemorrhage with the past 5 years

          -  LV thrombus visualized by either echocardiography or contrast LV angiogram

          -  Other severe concurrent illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan J. Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Heart Institute Foundation</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 2K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute de Cardiologie, Hopital Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>July 24, 2008</last_update_submitted>
  <last_update_submitted_qc>July 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2008</last_update_posted>
  <keyword>angiogenesis</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 8, 2009</submitted>
    <returned>October 8, 2009</returned>
    <submitted>July 30, 2015</submitted>
    <returned>August 28, 2015</returned>
    <submitted>October 13, 2015</submitted>
    <returned>November 13, 2015</returned>
    <submitted>January 12, 2016</submitted>
    <returned>February 10, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

